Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
#2845 Primary Tumour Resection and PRRT of NEN Stage IV - Are There Differences in Grading?
Introduction: The resection of primary tumours (PT) in patients with stage IV NEN is still a matter of debate. The resection of tumours with a low proliferation index (G1/G2) is more accepted then the resection of high proliferative tumours (G3-NET / G3-NEC).
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Kaemmerer D, Trwznik M, Hörsch D, Baum R, Hommann M,
Keywords: Surgery, Primary tumor, PRRT, Grading,
Introduction: In advanced NETs antiproliferative treatment options beyond somatostatin analogues remain limited. Temozolomide (TMZ) has shown efficacy in NETs alone or combined with other drugs.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author:
Authors: Pavel M, Denecke T, Lahner H, Hörsch D, Rinke A,
Keywords: lanreotide, temozolomide, somatostatin analogues, combination therapy, progressive advanced NET, SONNET,
Introduction: The tryptophan hydroxylase inhibitor telotristat ethyl (TE) significantly reduced bowel movement (BM) frequency versus placebo (pbo) in patients (pts) with carcinoid syndrome (CS) in the TELESTAR study.
Conference: 14th Annual ENETSConcerence (2017)
Presenting Author:
Authors: Anthony L, Kulke M, Hörsch D, Bergsland E, Öberg K,
Introduction: Peptide receptor radionuclide therapy (PRRT) is an highly effective therapeutic option to treat advanced neuroendocrine neoplasms (NEN). However, it is still unclear whether resection of primary tumors improves overall survival (OS) after PRRT.
Conference: 14th Annual ENETSConcerence (2017)
Presenting Author: Kaemmerer D
Authors: Kaemmerer D, Twrznik M, Hommann M, Hörsch D, Baum R,
Introduction: Telotristat ethyl (TE) is an oral tryptophan hydroxylase inhibitor in development for treating CS symptoms. During the double-blind treatment [DBT] period of the phase 3, 12-week, placebo-controlled TELESTAR study, TE was well tolerated and significantly reduced bowel-movement frequency and u5-HIAA levels compared with placebo (PBO) in NET patients with CS treated with a SSA.
Conference: 14th Annual ENETSConcerence (2017)
Presenting Author:
Authors: Pavel M, Hörsch D, Hoffmanns P, Biran T, Houchard A,
Keywords: carcinoid syndrome, 5-HIAA, telotristat,